Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
15
09
2021
accepted:
06
04
2022
pubmed:
17
5
2022
medline:
30
6
2022
entrez:
16
5
2022
Statut:
epublish
Résumé
The anti-α4β7 integrin antibody vedolizumab (VDZ) is successfully used for the treatment of inflammatory bowel diseases. However, only a subgroup of patients respond to therapy. VDZ is administered at a fixed dose, leading to a wide range of serum concentrations in patients. Previous work from our group showed a dose-dependent preferential binding of VDZ to effector compared with regulatory CD4 + T cells. Therefore, we aimed to determine the dose-dependent binding profile of VDZ to other leukocyte subsets. We characterized α4β7 integrin expression on CD8 + T cells, CD19 + B cells, CD14 + monocytes, natural killer cells, and eosinophils from patients with inflammatory bowel disease and healthy controls. We studied the binding of VDZ to these cells at different concentrations and investigated the functional consequences for dynamic adhesion and transmigration in vitro . The expression of α4β7 differed between the analyzed leukocyte subsets and was significantly higher on eosinophils from inflammatory bowel disease patients compared with controls. Almost all α4β7-expressing cells from these subsets were bound by VDZ at a concentration of 10 μg/mL. Dynamic cell adhesion was significantly impaired in all subsets, but there were no dose-dependent differences in the inhibition of adhesion. Our data suggest that α4β7-expressing CD8 + T cells, CD19 + B cells, CD14 + monocytes, natural killer cells, and eosinophils are a target of VDZ. However, there do not seem to be concentration-dependent differences, regarding the effects on these cells in the clinically relevant range. Thus, the reported exposure-efficacy characteristic of VDZ can probably mainly be attributed to CD4 + T-cell subsets.
Identifiants
pubmed: 35575178
doi: 10.14309/ctg.0000000000000494
pii: 01720094-202206000-00001
pmc: PMC9236604
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Integrins
0
vedolizumab
9RV78Q2002
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00494Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Zundler S, Becker E, Lou SchulzeL, et al. Immune cell trafficking and retention in inflammatory bowel disease: Mechanistic insights and therapeutic advances. Gut 2019;68(9):1688–700. doi:
Wiendl M, Becker E, Müller TM, et al. Targeting immune cell trafficking – insights from research models and implications for future IBD therapy. Front Immunol 2021;12:656452. doi:
Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7(9):678–89. doi:
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699–710. doi:
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369(8):711–21. doi:
Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: A state-of-the-art overview. BMC Med 2019;17(1):89–8. doi:
Al-Bawardy B, Ramos GP, Willrich MAV, et al. Vedolizumab drug Level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis 2019;25(3):580–6. doi:
Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24):2499–507. doi:
Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18(8):1470–9. doi:
Becker E, Dedden M, Gall C, et al. Residual homing of α4β7-expressing β1 + PI16 + regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut Published Online 2021:gutjnl-2021-324868. gutjnl-2021-324868. doi: 10.1136/gutjnl-2021-324868
doi: 10.1136/gutjnl-2021-324868
Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330(3):864–75. doi:
Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 2015;42(2):188–202. doi:
Verstockt B, Mertens E, Dreesen E, et al. Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-tumour necrosis factor [TNF] naïve and anti-TNF exposed IBD Patients. J Crohns Colitis 2020;14(3):332–41. doi:
Osterman MT, Rosario M, Lasch K, et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: Determining the potential for dose optimisation. Aliment Pharmacol Ther 2019;49(4):408–18. doi:
Guidi L, Pugliese D, Panici Tonucci T, et al. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United Eur Gastroenterol J 2019;7(9):1189–97. doi:
Ungaro RC, Yarur A, Jossen J, et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J Crohns Colitis 2019;13(8):963–9. doi:
Yarur AJ, Bruss A, Naik S, et al. Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases. Dig Dis Sci 2019;64(6):1651–9. doi:
Fischer A, Zundler S, Atreya R, et al. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 2016;65(10):1642–64. doi:
Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial. Lancet (London, England) 2014;384(9940):309–18. doi:
Funderburg NT, Stubblefield Park SR, Sung HC, et al. Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013;140(1):87–97. doi:
Bisping G, Lügering N, Lütke-Brintrup S, et al. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-γ) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. Clin Exp Immunol 2001;123(1):15–22. doi:
Corridoni D, Antanaviciute A, Gupta T, et al. Single-cell atlas of colonic CD8+ T cells in ulcerative colitis. Nat Med 2020;26(9):1480–90. doi:
Uzzan M, Colombel JF, Cerutti A, et al. B cell-activating factor (BAFF)-Targeted B cell therapies in inflammatory bowel diseases. Dig Dis Sci 2016;61(12):3407–24. doi:
Castro-Dopico T, Colombel JF, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: Back to the future. Curr Opin Pharmacol 2020;55:90–8. doi:
Panda SK, Colonna M. Innate lymphoid cells in mucosal immunity. Front Immunol 2019;10(MAY):861. doi:
Hisamatsu T, Erben U, Kühl AA. The role of T-cell subsets in chronic inflammation in celiac disease and inflammatory bowel disease patients: More common mechanisms or More differences?. Inflamm Intest Dis 2016;1(2):52–62. doi:
Filippone RT, Sahakian L, Apostolopoulos V, et al. Eosinophils in inflammatory bowel disease. Inflamm Bowel Dis 2019;25(7):1140–51. doi:
Loktionov A. Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders. World J Gastroenterol 2019;25(27):3503–26. doi:
Al-Haddad S, Riddell RH. The role of eosinophils in inflammatory bowel disease. Gut 2005;54(12):1674–5. doi:
Smyth CM, Akasheh N, Woods S, et al. Activated eosinophils in association with enteric nerves in inflammatory bowel disease. PLoS ONE 2013;8(5):e64216. doi:
Vermeire S, Lukáš M, Magro F, et al. Vedolizumab efficacy, safety, and pharmacokinetics with reduced frequency of dosing from every 4 weeks to every 8 weeks in patients with Crohn's disease or ulcerative colitis. J Crohns Colitis 2020;14(8):1066–73. doi:
Zeissig S, Rosati E, Dowds CM, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut 2019;68(1):25–39. doi:
Schleier L, Wiendl M, Heidbreder K, et al. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing. Gut 2020;69(2):252–63. doi:
Binder MT, Becker E, Wiendl M, et al. Similar inhibition of dynamic adhesion of lymphocytes from IBD patients to MAdCAM-1 by vedolizumab and etrolizumab-s. Inflamm Bowel Dis 2018;24(6):1237–50. doi:
Gismondi A, Morrone S, Humphries MJ, et al. Human natural killer cells express VLA-4 and VLA-5, which mediate their adhesion to fibronectin. J Immunol 1991;146(1):384–92.
Matsumoto K, Sterbinsky SA, Bickel CA, et al. Regulation of α4 integrin-mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1. J Allergy Clin Immunol 1997;99(5):648–56. doi:
Rabinowich H, Manciulea M, Herberman RB, et al. Beta1 integrin-mediated activation of focal adhesion kinase and its association with Fyn and Zap-70 in human NK cells. J Immunol 1996;157(9):3860–8.
Sun H, Liu J, Zheng YJ, et al. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. Dev Cel 2014;30(1):61–70. doi:
Zundler S, Schillinger D, Fischer A, et al. Blockade of αeβ7 integrin suppresses accumulation of CD8 + and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut 2017;66(11):1936–48. doi:
Crooks CV, Cross ML, Wall CR. Age-related differences in integrin expression in peripheral blood lymphocytes. Immun Ageing 2010;7(1):5. doi:
Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn's disease patients stratified by age. Adv Ther 2017;34(2):542–59. doi: